MYH14 and ocular melanoma: Much remains unclear about the mechanism of action of the drug, in particular, the apparent increase in Ca2+ sensitivity of OM, which suggests a complex mechanistic basis of action involving perturbation of the thin/thick filament regulatory state of the sarcomere mediated by binding to myosin allosteric sites coupled to inorganic phosphate (Pi) release [16].